These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25907159)

  • 21. Idebenone in Friedreich ataxia and Leber's hereditary optic neuropathy: close mechanisms, similar therapy?
    Schiff M; Rustin P
    Brain; 2016 Jul; 139(Pt 7):e39. PubMed ID: 27095078
    [No Abstract]   [Full Text] [Related]  

  • 22. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy: predicting the severity of Duchenne muscular dystrophy: implications for treatment.
    Kyriakides T; Pegoraro E; Hoffman EP; Piva L; Cagnin S; Lanfranchi G; Griggs RC; Nelson SF
    Neurology; 2011 Nov; 77(20):1858; author reply 1858-9. PubMed ID: 22084278
    [No Abstract]   [Full Text] [Related]  

  • 23. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.
    Hori YS; Kuno A; Hosoda R; Tanno M; Miura T; Shimamoto K; Horio Y
    J Pharmacol Exp Ther; 2011 Sep; 338(3):784-94. PubMed ID: 21652783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic evaluation of idebenone.
    Becker C; Bray-French K; Drewe J
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1437-44. PubMed ID: 20955109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
    Escolar DM; Buyse G; Henricson E; Leshner R; Florence J; Mayhew J; Tesi-Rocha C; Gorni K; Pasquali L; Patel KM; McCarter R; Huang J; Mayhew T; Bertorini T; Carlo J; Connolly AM; Clemens PR; Goemans N; Iannaccone ST; Igarashi M; Nevo Y; Pestronk A; Subramony SH; Vedanarayanan VV; Wessel H;
    Ann Neurol; 2005 Jul; 58(1):151-5. PubMed ID: 15984021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel use of idebenone in Leber's hereditary optic neuropathy in Hong Kong.
    Cheng SW; Ko CH; Yau SK; Mak C; Yuen YF; Lee CY
    Hong Kong Med J; 2014 Oct; 20(5):451-4. PubMed ID: 25307075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eteplirsen in the treatment of Duchenne muscular dystrophy.
    Lim KR; Maruyama R; Yokota T
    Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How effective are antioxidants in preventing respiratory decline in individuals with Duchenne muscular dystrophy with progressive worsening of breathing? A Cochrane Review summary with commentary.
    Oral A
    Dev Med Child Neurol; 2022 Sep; 64(9):1059-1062. PubMed ID: 35746858
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of idebenone treatment in a patient with DNAJC30-associated Leigh Syndrome.
    Dzwilewski K; Chojnowski K; Krygier M; Zawadzka M; Chylińska M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2024; 58(4):468-470. PubMed ID: 39132756
    [No Abstract]   [Full Text] [Related]  

  • 32. Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.
    Hafner P; Bonati U; Erne B; Schmid M; Rubino D; Pohlman U; Peters T; Rutz E; Frank S; Neuhaus C; Deuster S; Gloor M; Bieri O; Fischmann A; Sinnreich M; Gueven N; Fischer D
    PLoS One; 2016; 11(1):e0147634. PubMed ID: 26799743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Questions about efficacy of exon-skipping therapy for duchenne muscular dystrophy.
    Bhagavati S
    Ann Neurol; 2014 Feb; 75(2):326-9. PubMed ID: 24327535
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
    McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
    Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idebenone: A Review in Leber's Hereditary Optic Neuropathy.
    Lyseng-Williamson KA
    Drugs; 2016 May; 76(7):805-13. PubMed ID: 27071925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns-an Alternative Viewpoint.
    Irwin AN; Herink MC
    Pharmacotherapy; 2017 Oct; 37(10):e109-e111. PubMed ID: 28741800
    [No Abstract]   [Full Text] [Related]  

  • 38. Daily or alternative, that is the question: steroid therapy for Duchenne muscular dystrophy patients.
    Liang WC; Nishino I
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):591. PubMed ID: 23355805
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of steroids on surgical experiences of patients with duchenne muscular dystrophy.
    Dooley JM; Gordon KE; MacSween JM
    Pediatr Neurol; 2010 Sep; 43(3):173-6. PubMed ID: 20691938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.
    Timpani CA; Hayes A; Rybalka E
    Orphanet J Rare Dis; 2017 May; 12(1):100. PubMed ID: 28545481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.